On September 12, 2026, Chainflip, a cross-chain swap protocol, halted all trading after an attacker exploited a flaw in its Tron network settlement path, draining 736,442.17 USDT. The attack involved manipulating the memo field of a transaction, causing multiple unauthorized payouts. While the blockchain and other functions remain operational, swaps, deposits, and withdrawals are suspended to prevent further losses. Chainflip has fixed the vulnerability and promised to reimburse affected users once the network restarts, though no timeline or detailed compensation plan has been provided yet. Users are advised to check their swap status via the protocol's block explorer and avoid sending funds until operations resume.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
